News

Abridge deepens AI bets with Eli Lilly, NVIDIA and Artisight partnerships

On 11 June 2026, Abridge unveiled what it calls the first AI-native clinician intelligence platform — extending its ambient-documentation product into billing, clinical decision support, payer adjudication and pharmaceutical trial screening — alongside a set of strategic partnerships.

Eli Lilly — The drugmaker Eli Lilly made a strategic equity investment in Abridge (amount undisclosed). The tie-up centres on clinical trials: Abridge's new life-sciences module can surface trial eligibility from within the clinical conversation itself, feeding the patient pipeline Lilly needs to accelerate enrolment.

NVIDIA — NVIDIA, already a backer via its NVentures arm, is co-developing with Abridge the first foundation model for clinical conversations — trained on doctor-patient dialogue rather than a general LLM adapted for medicine.

Artisight — Abridge also partnered with Artisight, an NVIDIA-backed smart-hospital company using computer vision for patient monitoring, combining room-sensor data with ambient documentation across a hospital stay.

Abridge has raised roughly $830M to date, most recently a $316M Series E extension in April 2026 at a $5.3B valuation. The platform is live at more than 300 health systems — including Northwestern Medicine, Emory Healthcare and Johns Hopkins — supporting upward of 100 million clinical conversations a year.

Read more: Fortune

More top stories